Acute Coronary Syndrome
Conditions
Interventions
Low dose ticagrelor group:Ticagrelor 90 mg bid + aspirin 100 mg qd was maintained until 1 month after PCI, and after 1 month, it was changed to ticagrelor 60 mg bid + aspirin 100 mg qd until 1 year af
Standard dose ticagrelor group:Ticagrelor 90 mg bid + aspirin 100 mg qd was maintained until 1 year after PCI.
Clopidogrel group:Clopidogrel 75mg qd + aspirin 100mg qd maintained for 1 year after PCI.
Sponsors
Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Eligibility
Sex/Gender
All
Age
65 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Age greater than or equal to 65 years old; 2. Diagnosed with ACS; 3. Coronary artery disease confirmed by angiography and intended for PCI.
Exclusion criteria
Exclusion criteria: 1. Contraindications for coronary intervention; 2. Plan to use other ADP receptor blockers; 3. Long-term anticoagulation; 4. Known bleeding tendency or coagulation disorder; 5. History of intracranial hemorrhage; 6. Central nervous system tumor or intracranial vascular abnormalities (such as aneurysm, arteriovenous malformation); 7. Intracranial or spinal cord surgery within 5 years; 8. Gastrointestinal bleeding within the past 6 months or within the past 30 days Major surgery; 9. History of previous ischemic stroke; 10. Risk of bradycardia events (eg, sick sinus syndrome or second/third-degree atrioventricular block) unless permanent pacemaker therapy has been received; 11. Severe liver disease; 12. Renal failure requiring dialysis; 13. Combined with malignant tumor or other end-stage diseases that seriously affect survival; 14. Participated in other clinical studies within the past 30 days.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adenosine diphosphate-induced platelet-fibrin clot strength, MAADP; | — |
Secondary
| Measure | Time frame |
|---|---|
| ADP-induced platelet inhibition rate;Platelet-fibrin clot strength, MA;Platelet aggregation rate;Composite endpoint of MACCE, including all-cause death, non-fatal MI, stent thrombosis, non-fatal stroke, target vessel revascularization;Composite endpoint of all bleeding events, including BARC bleeding definition types 1, 2, 3, and 5.;Adverse events such as drug-related dyspnea, bradycardia, syncope; | — |
Countries
China
Contacts
Public ContactJie Zhao
Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Outcome results
None listed